Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

NSG BioLabs Drives Biotech Innovation in Singapore and Southeast Asia through EnterpriseSG and Merck Collaborations, Supported by Investments from Celadon Partners and ClavystBio

Wednesday, May 08, 2024

NSG BioLabs, a prominent provider of biotech co-working laboratory and office spaces in Singapore, has announced collaborations with Enterprise Singapore (EnterpriseSG) and Merck, a leading science and technology company. These partnerships aim to strengthen the biotech landscape by providing resources such as funding, expertise, and networks to support startup research and development (R&D). Additionally, the company has successfully concluded a US$14.5 million financing round led by Celadon Partners and ClavystBio, demonstrating confidence in NSG BioLabs' capabilities and its role in fostering scientific innovation and business growth.

Since its establishment in 2019, NSG BioLabs has played a vital role in supporting innovators across various sectors including health, biomedical, agrifood, and industrial biotechnology. With the largest co-working biotech laboratory and office footprint in Singapore and a vast network of partners and industry experts, NSG BioLabs has assisted over 40 resident companies, ranging from startups to multinationals. These resident startups alone have collectively raised nearly US$400 million in funding and have contributed significantly to job creation.

NSG BioLabs, expressed her commitment to nurturing Singapore's biotech ecosystem through collaboration and support from key stakeholders. The renewed partnership with EnterpriseSG underscores NSG BioLabs' dedication to accelerating the development and commercialization of deep tech solutions, particularly in fields such as precision medicine.

Dr. Clarice Chen, Director of Healthcare and Biomedical at EnterpriseSG, emphasized the agency's commitment to driving innovation in the biotech sector by providing capital, infrastructure, and expertise. This collaborative effort aims to strengthen Singapore's position in precision medicine and revolutionize healthcare delivery.

With the strategic investment round led by Celadon Partners and ClavystBio, NSG BioLabs plans to enhance its offerings and expand its facilities to meet the growing demands of biotech startups and multinational companies in Singapore and Southeast Asia.

Celadon Partners, expressed confidence in NSG BioLabs' ability to offer compelling solutions for the burgeoning biotech sector in Southeast Asia. Similarly, Khoo Shih Ph.D., CEO of ClavystBio, highlighted the investment's alignment with ClavystBio's mission to accelerate breakthrough science into health impact through strategic partnerships.

NSG BioLabs' partnership with Merck will further empower its residents by providing access to special terms for reagents and equipment, as well as biopharma processing expertise and consultation for scaling-up production.

With three sites totaling 35,000 square feet, NSG BioLabs solidifies its position as a key hub for biotech innovation in the region. Coupled with its recent partnerships and strategic investments, NSG BioLabs is poised to enhance its value-add offerings and continue fostering a vibrant community of biotech innovators.



magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024